Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22337324 | 1.00 | HINT1 (0.39) | HINT1SLC29A1ADORA2AADORA1ADORA2B | |
| SCHEMBL26808575 | 0.92 | SLC29A1 (0.38) | HINT1SLC29A1ADORA2AADORA1ADORA2B | |
| SCHEMBL22337062 | 0.84 | ADORA1 (0.49) | ADORA1NT5E | |
| SCHEMBL22337055 | 0.84 | ADORA1 (0.49) | ADORA1NT5E | |
| SCHEMBL22337175 | 0.84 | HINT1 (0.49) | HINT1NT5E | |
| SCHEMBL26808260 | 0.80 | SLC29A1 (0.42) | HINT1SLC29A1ADORA2AADORA1ADORA2B | |
| SCHEMBL26808405 | 0.80 | SLC29A1 (0.42) | HINT1SLC29A1ADORA2AADORA1ADORA2B | |
| SCHEMBL8533343 | 0.78 | HINT1 (0.40) | HINT1SLC29A1ADORA2AADORA1ADORA2B | |
| SCHEMBL26808594 | 0.76 | HINT1 (0.48) | HINT1NT5E | |
| SCHEMBL26808538 | 0.76 | ADORA1 (0.49) | SLC29A1ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357306-A1 | SYNTHESIS OF 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2020163415-A1 | SYNTHESIS OF 1,2,5-TRI-0-BENZ0YL-3-DIBENZYLAMIN0-3-DE0XYRIB0SE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357306-A1 | SYNTHESIS OF 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE AS INTERMEDIATE FOR PRODUCING 3'-AMINO-3'-DEOXYADENOSINE AND 3'-AMINO-3'-DEOXYGUANOSINE AND THE PROTECTED DERIVATIVES THEREOF | STING1, CGAS, AMPD3 | HINT1 152/4885SLC29A1 468/4885ADORA2A 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.